Jpn. J. Pharmacol. 85 (3), 331-334 (2001)

Utilization of Telemetry System to Assess the Cardiovascular Profile of AH-1058, a New Cardioselective Ca2+ Channel Blocker, in Conscious Dogs

Akira Takahara1,*, Hideki Dohmoto1, Ryota Yoshimoto1, Atsushi Sugiyama2 and Keitaro Hashimoto2

1Pharmaceutical Research Laboratories, Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki-ku, Kawasaki 210-8681, Japan
2Department of Pharmacology, Yamanashi Medical University, Tamaho-cho, Nakakoma-gun, Yamanashi 409-3898, Japan
*Corresponding author. FAX: +81-44-210-5875

Abstract: Cardiovascular effects of a new Ca2+ channel blocker AH-1058, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[(E)-3-(3-methoxy-2-nitro)phenyl-2-propenyl]piperidine hydrochloride, were assessed in conscious dogs using a new telemetry system. AH-1058 (0.03, 0.1 and 0.3 mg/kg, i.v.) reduced systolic blood pressure and the maximal upstroke velocity of the left ventricular pressure and increased the heart rate in a dose-dependent manner without affecting the diastolic blood pressure; each of these responses lasted for several hours. These results support the previous knowledge that AH-1058 is a long-lasting cardiodepressive drug. The telemetry system provided important information for predicting favorable clinical effects of AH-1058.

Keywords: AH-1058, Ca2+ channel blocker, Cardiovascular action

[Back to TOC]